Multiple Myeloma Gammopathies

POEMS syndrome remains a mystery after 40 years

To the Editor:

The acronym POEMS was coined by Bardwick et al. in 1980 to describe a paraneoplastic syndrome due to an underlying monoclonal gammopathy [1]. Although our understanding of its manifestations, treatment and prognosis has advanced in recent years, the critical genetic events occurring in its plasma cells are not fully elucidated. Chen et al. reported a highly heterogenous mutational profile in 42 POEMS patients [2]. The results were largely concordant with a previous study from Japan; however, significantly discordant findings were also evident [3].

Both studies utilized a two-step approach, whole exome followed by targeted sequencing, to tackle the somatic mutations in bone marrow plasma cells prepared by CD138 magnetic beads sorting. Of the seven recurrently mutated genes identified by Nago et al., five were validated by Chen et al. However, the later study reported a much higher mutation frequency (87.5% vs. 45.0%) as well as unique driver mutations associated with multiple myeloma in POEMS patients. Beside different sample size and sequencing depth mentioned by Chen et al., other possible explanations underlying the discordance also need to be considered, such as patient characteristics. Compared to the newly diagnosed cases with classic λ light chain-restriction in Chen’s study, Nago et al. included relapsed as well as non-λ cases. Of note, only one of the five (20.0%) relapsed patients had a mutation.

The real burning question is whether these mutations happen in the POEMS-specific clone, which only represents a minor population (median 14.7%) among bone marrow plasma cells and was not isolated in both studies [4]. In addition, this clone was only detected in 65.7% POEMS patients in a study when using routinely available diagnostic tools, including flow cytometry, immunohistochemistry, and/or in situ hybridization [5]. Even with the advance of deep sequencing technologies, the detection rate (50.0–82.8%) is still not satisfactory [4, 6]. Single-cell genomic sequencing has the potential to answer this question.

Markedly elevated circulating vascular endothelial growth factor (VEGF) level is a distinct feature of POEMS syndrome and could account for most of its clinical manifestations. The link between reported mutations and VEGF elevation is missing. Hypoxia-sensing pathway is the master regulator of VEGF expression, and mutations in its components, both hereditary (e.g., Chuvash polycythemia) and sporadic (e.g., glioblastoma multiforme) are associated with raised circulating VEGF [7, 8]. It is noteworthy that genes of hypoxia-sensing pathway were not included in the targeted sequencing panels of both studies. Their whole exome sequencing may not be capable to detect low frequency mutations due to the limited sequencing depth, which was also corroborated by the observation that targeted sequencing revealed more mutations in both studies. Given that alterations of hypoxia-sensing components usually lead to modest VEGF elevation, interactions with the currently reported POEMS mutations could be further explored.

Even though mechanistic questions are yet to be answered, revealing the genomic profile of POEMS deepens our understanding of this mysterious disease and its pathogenesis awaits the dawn hopefully in the near future.


  1. 1.

    Bardwick PA, Zvaifler NJ, Gill GN, Newman D, Greenway GD, Resnick DL. Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome. Report on two cases and a review of the literature. Med (Baltim). 1980;59:311–22.

    CAS  Article  Google Scholar 

  2. 2.

    Chen J, Gao XM, Zhao H, Cai H, Zhang L, Cao XX, et al. A highly heterogeneous mutational pattern in POEMS syndrome. Leukemia. 2020.

  3. 3.

    Nagao Y, Mimura N, Takeda J, Yoshida K, Shiozawa Y, Oshima M, et al. Genetic and transcriptional landscape of plasma cells in POEMS syndrome. Leukemia. 2019;33:1723–35.

    CAS  Article  Google Scholar 

  4. 4.

    Isshiki Y, Mimura N, Oshima M, Kayamori K, Seki M, Nagai Y, et al. Single-cell analyses unravel unique features of plasma cell clones in POEMS syndrome. ASH Annual Meeting. 2020. Poster 3170.

  5. 5.

    Dao LN, Hanson CA, Dispenzieri A, Morice WG, Kurtin PJ, Hoyer JD. Bone marrow histopathology in POEMS syndrome: a distinctive combination of plasma cell, lymphoid, and myeloid findings in 87 patients. Blood. 2011;117:6438–44.

    CAS  Article  Google Scholar 

  6. 6.

    Bender S, Javaugue V, Saintamand A, Ayala MV, Alizadeh M, Filloux M, et al. Immunoglobulin variable domain high-throughput sequencing reveals specific novel mutational patterns in POEMS syndrome. Blood. 2020;135:1750–8.

    Article  Google Scholar 

  7. 7.

    Gordeuk VR, Sergueeva AI, Miasnikova GY, Okhotin D, Voloshin Y, Choyke PL, et al. Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood. 2004;103(May):3924–32.

    CAS  Article  Google Scholar 

  8. 8.

    Yalaza C, Ak H, Cagli MS, Ozgiray E, Atay S, Aydin HH. R132H mutation in IDH1 gene is associated with increased tumor HIF1-alpha and serum VEGF levels in primary glioblastoma multiforme. Ann Clin Lab Sci. 2017;47:362–4.

    CAS  PubMed  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Chen Wang.

Ethics declarations

Conflict of interest

The author declares no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wang, C. POEMS syndrome remains a mystery after 40 years. Leukemia (2021).

Download citation


Quick links